PNC-27
Also known as p53-derived anticancer peptide, HDM-2-binding peptide
A synthetic p53-derived research peptide studied preclinically for cancer-cell membrane effects and HDM-2-related mechanisms, not an approved cancer therapy.
Overview
PNC-27 is a synthetic peptide derived from a p53 protein segment and linked to a membrane-penetrating sequence in research designs. It is discussed mostly in preclinical oncology contexts.
The Science
The proposed mechanism involves interaction with HDM-2 and selective membrane effects in cancer cells. That makes it scientifically interesting, but also means claims should be held to oncology-level evidence standards.
- p53/HDM-2 biology - tumor suppressor pathway context.
- Cancer-cell membrane effects - preclinical work focuses on selective tumor-cell disruption.
- Translational uncertainty - cell and animal findings are not clinical proof.
Evidence Snapshot
PNC-27 is not an approved cancer treatment. It belongs in a research library as an example of p53-derived peptide design and the gap between preclinical signal and clinical validation.
Related
More in Longevity
5-Amino-1MQ
Research compoundLongevity
Not a peptideSmall molecule
A small-molecule compound that researchers and self-experimenters study for its effects on metabolism, body composition, cellular energy, and healthy aging. Often discussed as a tool for understanding and potentially optimizing metabolic flexibility through NNMT inhibition.
B12
FDA-approvedLongevity
Not a peptideVitamin
An essential water-soluble vitamin required for red blood cell formation, nervous-system function, DNA synthesis, and one-carbon metabolism; it is not a peptide.
Cardiogen
Research compoundLongevity
A short bioregulator peptide discussed in cardiovascular-aging research traditions, usually represented by the tetrapeptide Ala-Glu-Asp-Arg.